| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 11.9 | 10.0 | 8.7 |
| Total income | 2937.0 | 2432.0 | 2816.0 |
| Exceptional items | -56.4 | 0.0 | 12.5 |
| Net profit | 80.5 | 98.8 | 132.0 |
| Operating margin | 3.7% | 5.4% | 6.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -39.00% |
|---|---|
| Net profit, quarter on quarter | -18.50% |
BSE results filing, NSE: BLUESTARCO. Figures extracted from the filing.
Blue Star Ltd: key numbers
- Share price
- ₹1,529.50
- Market cap
- ₹31,449 Cr
- Revenue (annual)
- ₹12,402 Cr
- Net profit (annual)
- ₹527.7 Cr
- P/E (TTM)
- 61.8×Sector 44.2×
- Promoter holding
- 36.50%+0.01% QoQ
- FII holding
- 12.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Blue Star Ltd
All →Blue Star Annual General Meeting
Blue Star Limited has issued a Postal Ballot notice seeking shareholder approval for the appointment of Mr. Nikhilesh Panchal as an Independent Director.
Blue Star Legal & Regulatory
Blue Star Limited informed that W.J. Towell & Co LLC has filed an annulment petition in the Dubai Court of Appeal challenging a prior favourable arbitration award.
Blue Star Debt & Borrowing: ₹100 Cr
Blue Star Limited has fixed September 18, 2026, as the record date for its listed Commercial Paper. The maturity amount for this security is Rs. 100 Crores.
- Value
- ₹100.0 Cr
Blue Star Merger & Restructuring Worth ₹40 Cr
Blue Star Limited completed the slump sale of its MedTech division, housed under subsidiary Blue Star E&E, to Cyrix Healthcare for Rs 40 Crore.
- Value
- ₹40.00 Cr
Blue Star Merger & Restructuring Worth ₹40 Cr
Blue Star’s subsidiary, Blue Star E&E, signed a Business Transfer Agreement to sell its MedTech division to Cyrix Healthcare for up to ₹40 Crore.
- Value
- ₹40.00 Cr
Blue Star Earnings Call Transcript: Key Takeaways
Blue Star missed margin expectations significantly due to inability to pass on commodity costs and a delayed summer. While revenue grew 13%, operational performance was hit by high-cost inventory and aggressive discounting to maintain market share.
- Call
- Guides 18% growth